Dear Cms, Toll Matters
Sunday, September 27, 2020
Your authorities at work. Here's the pertinent quote from Melinda Beck's Wall Street Journal article on proton beam therapy:
But about insurers are balking at paying premium rates for proton therapy for such mutual cancers without to a greater extent than show that it does meliorate patient outcomes—ideally from randomized controlled trials. Several are forthwith nether way, only it volition live on years before results are clear.
Most Medicare regions comprehend proton therapy for prostate—at close $1,100 per handling session, compared alongside $600 for IMRT. But several major insurers stopped later a 2012 written report constitute it has no added long-term benefit. Men alongside prostate cancer had made upwardly 70% of patients at about proton centers; forthwith they are less than one-half the facilities’ customers nationwide.
It's fourth dimension for the authorities to bring the spine together with judgment to modify its pricing for this therapy.
As I bring noted earlier, where are the Triple Aim advocates on this point?
But about insurers are balking at paying premium rates for proton therapy for such mutual cancers without to a greater extent than show that it does meliorate patient outcomes—ideally from randomized controlled trials. Several are forthwith nether way, only it volition live on years before results are clear.
Most Medicare regions comprehend proton therapy for prostate—at close $1,100 per handling session, compared alongside $600 for IMRT. But several major insurers stopped later a 2012 written report constitute it has no added long-term benefit. Men alongside prostate cancer had made upwardly 70% of patients at about proton centers; forthwith they are less than one-half the facilities’ customers nationwide.
It's fourth dimension for the authorities to bring the spine together with judgment to modify its pricing for this therapy.
As I bring noted earlier, where are the Triple Aim advocates on this point?